Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
ALX ONCOLOGY HOLDINGS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $0.00 | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $1.18M | -75.4% |
| 2019 | $4.80M | +132.0% |
| 2018 | $2.07M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2020 | $527.0K | -59.3% | -19.5% |
| March 31, 2020 | $655.0K | — | -47.9% |
| September 30, 2019 | $1.26M | — | -3.0% |
| June 30, 2019 | $1.29M | — | — |
- Over the 2018–2022 period, ALX ONCOLOGY HOLDINGS INC’s revenue (asc 606) has declined by 100.0% (from $2.07 million to $0.00).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 9, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: